Vernalis (Apokyn & Vernalis US Commercial Operations) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

Vernalis (Apokyn & Vernalis US Commercial Operations) General Information

Description

Developer of pharmaceutical products headquartered in Wokingham, England. The company develops and applies fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives, inflammation and integrates fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
  • Oakdene Court, 613 Reading Road
  • Winnersh
  • Wokingham RG41 5UA
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vernalis (Apokyn & Vernalis US Commercial Operations) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vernalis (Apokyn & Vernalis US Commercial Operations)‘s full profile, request access.

Request a free trial

Vernalis (Apokyn & Vernalis US Commercial Operations) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vernalis (Apokyn & Vernalis US Commercial Operations)‘s full profile, request access.

Request a free trial